Interleukin-6 upregulates neuronal adenosine A1 receptors: Implications for neuromodulation and neuroprotection (Neuropsychopharmacology (2008) 33, (2237-2250) DOI: 10.1038/sj.npp.1301612);Interleukin-6 upregulates neuronal adenosine A1 receptors: Implications for neuromodulation and neuroprotection

Neuropsychopharmacology

Volumn 33, Issue 9, 2008, Pages 2237-2250

  Biber, Knut ^a   Pinto Duarte, A ^b,c   Wittendorp, M C ^a   Dolga, A M ^d   Fernandes, C C ^b,c   Von Frijtag Drabbe Kunzel J ^e   Keijser, J N ^d   De Vries, R ^a   Ijzerman, A P ^e   Ribeiro, J A ^b,c   Eisel, U ^d   Sebastiao A M ^b,c   Boddeke, H W G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adenosine A1 receptor; Brain inflammation; Cytokines; Excitotoxicity; Hypoxia; Seizures

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; CONVULSION; EXCITOTOXICITY; HYPOXIA; MALE; MOUSE; NERVE CELL NECROSIS; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEIZURE; SYNAPTIC TRANSMISSION;

EID: 47249146449     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.92     Document Type: Erratum

References (76)

1. 2 receptors. Eur J Pharmacol 227: 317-324.
2. Ali C, Nicole O, Docagne F, Lesne S, MacKenzie ET, Nouvelot A et al (2000). Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J Cereb Blood Flow Metab 20: 956-966.
3. Anderson WW, Collingridge GL (2001). The LTP program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J Neurosci Methods 108: 71-83.
4. Anderson WW, Collingridge GL (2007). Capabilities of the WinLTP data acquisition program extending beyond basic LTP experimental functions. J Neurosci Methods 162: 346-356.
5. 1 adenosine receptor binding during daily repeated pentylentetrazol-induced convulsions in different mouse brain areas. Neurosci Lett 132: 203-206.
6. 1 adenosine receptors in human temporal lobe epilepsy: a quantitative autoradiographic study. Neurosci Lett 163: 11-14.
7. Arrigoni E, Crocker AJ, Saper CB, Greene RW, Scammell TE (2005). Deletion of presynaptic adenosine A1 receptors impairs the recovery of synaptic transmission after hypoxia. Neuroscience 132: 575-580.
8. Asanuma M, Ogawa N, Nishibayashi S, Kondo Y, Mori A (1995). Effects of repeated injection of cyclosporin A on pentylenetetrazol-induced convulsion and cyclophilin mRNA levels in rat brain. Neurochem Res 20: 101-105.
9. 1 receptor inhibition of glutamate exocytosis and protein kinase C-mediated decoupling. J Neurochem 60: 1081-1086.
10. Bensadoun JC, Pereira de Almeida L, Dréano M, Aebischer P, Déglon N (2001). Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. Eur J Neurosci 14: 1753-1761.
11. 1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J Neurosci 17: 4956-4964.
12. Biber K, Lubrich B, Fiebich BL, Boddeke HW, van Calker D (2001). Interleukin-6 enhances expression of adenosine A(1) receptor mRNA and signaling in cultured rat cortical astrocytes and brain slices. Neuropsychopharmacology 24: 86-96.
13. Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D (2002). Increases vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 83: 167-175.
14. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA et al (1993). Neurologic diseases induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci 90: 10061-10065.
15. Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC (1999). Inflammatory cytokines IL-1α, IL-1β, Il-6, and TNF-α impart neuroprotection to an excitotoxin through distinct pathways. J Immunol 163: 3963-3968.
16. Chomczynski P, Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
17. Citri A, Malenka RC (2007). Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology, advance online publication, August 29, 2007 (DOI 10.1038/sj.npp.1301559).
18. Conroy SM, Nguyen V, Quina LA, Blakely-Gonzales P, Ur C, Netzeband JG et al (2004). Interleukin-6 produces neuronal loss in developing cerebellar granule neuron cultures. J Neuroimmunol 155: 43-54.
19. 1 receptor: analysis of the potential therapeutic effects obtained by its activation in the central nervous system. Curr Med Chem 9: 1923-1937.
20. d'Arcangelo G, Tancredi V, Onofri F, D Antuono M, Giovedi S, Benfenati F (2000). Interleukin-6 inhibits neurotransmitter release and the spread of excitation in the rat cerebral cortex. Eur J Neurosci 12: 1241-1252.
21. de Jong EK, Dijkstra IM, Hensens M, Brouwer N, van Amerongen M, Liem RSB et al (2005). Vesicle-mediated transport and release of CCL21 in endangered neurons: a possible explanation for microglia activation remote from a primary lesion. J Neurosci 25: 7548-7557.
22. de Luca G, Di Giorgio R M, Macaione S, Calpona PR, Costantino S, Di Paola ED et al (2004). Susceptibility to audiogenic seizure and neurotransmitter amino acid levels in different brain areas of IL-6-deficient mice. Pharmacol Biochem Behav 78: 75-81.
23. de Sarro G, Russo E, Ferreri G, Giuseppe B, Flocco MA, Di Paola E D et al (2004). Seizure susceptibility to various convulsant stimuli of knockout interleukin-6 mice. Pharmacol Biochem Behav 77: 761-766.
24. 1 receptor activation. Neuroreport 6: 1097-1100.
25. 2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci 24: 2905-2913.
26. Dragunow M (1988). Purinergic mechanisms in epilepsy. Prog Neurobiol 31: 85-108.
27. Dunwiddie TV, Masino SA (2001). The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24: 31-55.
28. 2B receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J Neurochem 66: 1426-1431.
29. Gadient RA, Otten UH (1997). Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog Neurobiol 52: 379-390.
30. Gerber U, Gahwiler BH (1994). GABAb and adenosine receptors mediate enhancement of the K+ current, IAHP, by reducing adenylyl cyclase activity in rat CA3 hippocampal neurons. J Neurophysiol 72: 2360-2367.
31. 1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 44: 877-885.
32. Gruol DL, Nelson TE (1997). Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 15: 307-339.
33. Herrmann O, Tarabin V, Suzuki S, Attigah N, Coserea I, Schneider A et al (2003). Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia. J Cereb Blood Flow and Metab 23: 406-415.
34. 1AR mRNA expression or G protein alpha-subunit content. J Neurochem 71: 221-230.
35. Jankowsky JL, Patterson PH (1999). Differential regulation of cytokine expression following pilocarpine-induced seizure. Exp Neurol 159: 333-346.
36. Kondziella D, Bidar A, Urfjell B, Sletvold O, Sonnewald U (2002). The pentylenetetrazole-kindling model of epilepsy in SAMP8 mice: behavior and metabolism. Neurochem Int 40: 413-418.
37. Lambert NA, Teyler TJ (1991). Adenosine depresses excitatory but not fast inhibitory synaptic transmission in area CA1 of the rat hippocampus. Neurosci Lett 122: 50-52.
38. Latini S, Pedata F (2001). Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79: 463-484.
39. Lehtimäki KA, Peltola J, Koskikallio E, Keranen T, Honkaniemi J (2003). Expression of cytokines and cytokine receptors in the rat brain after kainic acid-induced seizures. Brain Res Mol Brain Res 110: 253-260.
40. Lehtimäki KA, Keränen T, Huhtala H, Hurme M, Ollikainen J, Honkaniemi J et al (2004). Regulation of Il-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration. J Neuroimmunol 152: 121-125.
41. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)). Method Methods 25: 402-408.
42. A-mediated actions during hypoxia in the rat hippocampus. Brain Res 732: 261-266.
43. Loddick SA, Turnbull AV, Rothwell NJ (1998). Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 18: 176-179.
44. Lohse MJ, Lenschow V, Schwabe U (1984). Interaction of barbiturates with adenosine receptors in rat brain. Naunyn Schmiedebergs Arch Pharmacol 326: 69-74.
45. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL (2004). Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 279: 32869-32881.
46. Nelson TE, Netzeband JG, Gruol DL (2004). Chronic interleukin-6 exposure alters metabotropic glutamate receptor-activated calcium signalling in cerebellar Purkinje neurons. Eur J Neurosci 20: 2387-2400.
47. 1 receptors in the rat hippocampus: a quantitative autoradiographic study. Brain Res 458: 212-217.
48. 1 adenosine receptor regional density in the mouse brain: a quantitative autoradiographic study. Neuroscience 56: 711-716.
49. Peltola J, Hurme M, Miettinen A, Keranen T (1998). Elevated levels of interleukin-6 may occur in cerebrospinal fluid from patients with recent epileptic seizures. Epilepsy Res 31: 129-133.
50. Peltola J, Laaksonen J, Haapala AM, Hurme M, Rainesalo S, Keranen T (2002). Indicators of inflammation after recent tonicclonic epileptic seizures correlate with plasma interleukin-6 levels. Seizure 11: 44-46.
51. Peltola J, Palmio J, Korhonen L, Suhonen J, Miettinen A, Hurme M et al (2000). Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res 41: 205-211.
52. Penkowa M, Molinero A, Carrasco J, Hidalgo J (2001). Interleukin-6 deficiency reduces the brain inflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures. Neuroscience 102: 805-818.
53. 2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus. J Neurochem 93: 595-604.
54. Pizzi M, Sarnico I, Boroni F, Benarese M, Dreno M, Garotta G et al (2004). Prevention of neuron and oligodendroctye degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. Mol Cell Neurosci 25: 301-311.
55. Qiu Z, Sweeney DD, Netzeband JG, Gruol DL (1998). Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons. J Neurosci 18: 10445-10456.
56. Ribeiro JA (2005). What can adenosine neuromodulation do for neuroprotection? Curr Drug Targets CNS Neurol Disord 4: 325-329.
57. Rudolphi KA, Schubert P (1996). Purinergic interventions in traumatic and ischemic injury. In: Peterson PL, Willis PW (eds) Novel Thearapies for CNS Injuries. Boca Raton: New York, London, Tokyo: CRC Press Inc, pp 327-342.
58. 1 receptors in rat brain by in vivo treatment with RPIA: involvement of coated vesicles. Biochim Biophys Acta 1310: 168-174.
59. Samland H, Huitron-Resendiz S, Masliah E, Criado J, Hendriksen SJ, Campbell IL (2003). Profound increase in sensitivity to glutamatergic-but not to cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J Neurosci Res 73: 176-187.
60. Schurr A, Reid KH, Tseng MT, West C, Rigor BM (1986). Adaptation of adult brain tissue to anoxia and hypoxia in vitro. Brain Res 374: 244-248.
61. Schwaninger M, Neher M, Viegas E, Schneider A, Spranger M (1997). Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine. J Neurochem 69: 1145-1150.
62. Schwaninger M, Petersen N, Prinz S, Sallmann S, Neher M, Spranger M (2000). Adenosine-induced expression of interleukin-6 in astrocytes through protein kinase A and NF-IL-6. Glia 31: 51-58.
63. Sebastião AM, Cunha RA, de Mendonça A, Ribeiro JA (2000). Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats. Br J Pharmacol 131: 1629-1634.
64. Sebastião AM, de Mendonça A, Moreira T, Ribeiro JA (2001). Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J Neurosci 21: 8564-8571.
65. Sebastião AM, Stone TW, Ribeiro JA (1990). The inhibitory adenosine receptor at the neuromuscular junction and hippocampus of the rat: antagonism by 1,3,8-substituted xanthines. Br J Pharmacol 101: 453-459.
66. Staff NP, Jung HY, Thiagarajan T, Yao M, Spruston N (2000). Resting and active properties of pyramidal neurons in subiculum and CA1 of rat hippocampus. J Neurophysiol 84: 2398-2408.
67. Stone TW (2002). Purines and neuroprotection. Adv Exp Med Biol 513: 249-280.
68. 1 receptors are located predominantly on axons in the rat hippocampal formation. J Comp Neurol 363: 517-531.
69. Swartz KR, Liu F, Sewell D, Schochet T, Campbell I, Sandor M et al (2001). Interleukin-6 promotes post-traumatic healing in the central nervous system. Brain Res 896: 86-95.
70. Trussell LO, Jackson MB (1985). Adenosine-activated potassium conductance in cultured striatal neurons. Proc Natl Acad Sci USA 82: 4857-4861.
71. 1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study. Neuroscience 52: 843-854.
72. 1 receptors within rat hippocampus. Neurochem Res 26: 225-230.
73. van Wagoner NJ, Benveniste EN (1999). Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol 100: 124-139.
74. 1 receptor: functional expression and pharmacology. Eur J Pharmacol 487: 73-79.
75. Yan L, Burbiel JC, Maass A, Muller CE (2003). Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8: 537-576.
76. Yoon KW, Rothman SM (1991). Adenosine inhibits excitatory but not inhibitory synaptic transmission in the hippocampus. J Neurosci 11: 1375-1380.